[ Citizens United for Research in Epilepsy Catalyst Award | Research Funding ]
Event details
| Date | 06.07.2020 |
| Category | Call for proposal |
Aim: CURE funds research that has the potential to truly transform and save lives. The purpose of this funding opportunity is to stimulate and accelerate discovery and development of new, transformative therapies for epilepsy, moving promising, well-supported preclinical and/or clinical research closer to clinical application. The award is intended to support nimble development of data necessary to attract larger commercialization funding opportunities and is not intended to replace those opportunities. Projects based on novel biological pathways and/or highly differentiated therapeutic approaches which are likely to have a high probability of success transitioning to clinical development are strongly encouraged. The award is not intended to fund basic research on the mechanisms underlying epilepsy.
Projects supported by this award mechanism should advance research to clinical trial readiness through development of biomarkers, optimization of new entities based on entities with established proof-of -concept including pharmacokinetics/pharmacodynamics, safety profiles and/or improved formulations, as well as studies that advance preclinical findings to pilot clinical trials. Prospective pilot clinical trials where limited testing of a novel intervention is needed to inform the next step in the translational research may be considered. Priority areas include:
Funding: max. $250,000
Duration: 2 years
Eligibility: This award is available to independent researchers at or above the level of Assistant Professor (or equivalent) at universities and non-academic research institutions, including small biotechnology companies, that seek to develop new interventions for epilepsy. International applicants are welcome. Postdoctoral fellows may not apply for this award. All materials must be submitted in English.
How to Apply: All applicants must submit a Letter of Intent (LOI). The LOI should clearly and succinctly outline the specific aims and include a brief description of the justification and research plan according to the guidelines in the RFA. LOIs and full proposals (by invitation) must be submitted through proposalCENTRAL. To begin an application, applicants will need to create a professional profile, if one does not already exist. If EPFL will serve as your host institution, please use the following institution name in proposalCENTRAL: Ecole Polytechnique Fédérale de Lausanne EPFL. After the LOI has been evaluated, selected applicants will be invited to submit a full proposal. At this stage, a signature from an institutional representative will be required; for this, please contact the Research Office.
Deadline, Letter of Intent: 06-July-2020 (9:00 PM ET)
Further information
Projects supported by this award mechanism should advance research to clinical trial readiness through development of biomarkers, optimization of new entities based on entities with established proof-of -concept including pharmacokinetics/pharmacodynamics, safety profiles and/or improved formulations, as well as studies that advance preclinical findings to pilot clinical trials. Prospective pilot clinical trials where limited testing of a novel intervention is needed to inform the next step in the translational research may be considered. Priority areas include:
- Innovative approaches that can prevent, modify and/or arrest the development of acquiredepilepsy.
- Development of novel approaches to prevent onset or halt the progression of severe pediatricepilepsies.
- New, effective treatments for the >30% of the epilepsy population who are pharmaco-resistant.
Funding: max. $250,000
Duration: 2 years
Eligibility: This award is available to independent researchers at or above the level of Assistant Professor (or equivalent) at universities and non-academic research institutions, including small biotechnology companies, that seek to develop new interventions for epilepsy. International applicants are welcome. Postdoctoral fellows may not apply for this award. All materials must be submitted in English.
How to Apply: All applicants must submit a Letter of Intent (LOI). The LOI should clearly and succinctly outline the specific aims and include a brief description of the justification and research plan according to the guidelines in the RFA. LOIs and full proposals (by invitation) must be submitted through proposalCENTRAL. To begin an application, applicants will need to create a professional profile, if one does not already exist. If EPFL will serve as your host institution, please use the following institution name in proposalCENTRAL: Ecole Polytechnique Fédérale de Lausanne EPFL. After the LOI has been evaluated, selected applicants will be invited to submit a full proposal. At this stage, a signature from an institutional representative will be required; for this, please contact the Research Office.
Deadline, Letter of Intent: 06-July-2020 (9:00 PM ET)
Further information
- More information about the program is available here
- The Request for Applications (RFA) can be found here
- The application portal can be found here
- For any other questions, please contact the Research Office
Practical information
- General public
- Free